The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications - 18/06/18
, Ye Wang b, Peter S. Kirk a, James M. Dupree a, Eric A. Singer c, Steven L. Chang bAbstract |
Objective |
To determine the impact of physicians' financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential.
Materials and Methods |
We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs.
Results |
The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect.
Conclusion |
There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure:James M. Dupree receives salary support fromBlue Cross Blue Shield of Michiganfor his role as the co-director of the Michigan Value Collaborative and his involvement in the Michigan Urological Surgery Improvement Collaborative. The remaining authors declare that they have no relevant financial interests. |
|
| Funding Support:This work was supported byP30CA072720(EAS). |
Vol 117
P. 50-56 - juillet 2018 Retour au numéro
Article précédent
- Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference?
- Harsha R. Mittakanti, Simon L. Conti, Alan C. Pao, Glenn M. Chertow, Joseph C. Liao, John T. Leppert, Christopher S. Elliott
- Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States
- Wen Liu, Dattatraya Patil, David H. Howard, Renee H. Moore, Heqiong Wang, Martin G. Sanda, Christopher P. Filson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?